Miltefosine NEW
Price | $47 | $56 | $85 |
Package | 50mg | 100mg | 200mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-19 |
Product Details
Product Name: Miltefosine | CAS No.: 58066-85-6 |
Purity: 99.51% | Supply Ability: 10g |
Release date: 2024/11/19 |
Product Introduction
Bioactivity
Name | Miltefosine |
Description | Miltefosine (HePC) is the treatment of visceral and cutaneous leishmaniasis drug , and is proceeding clinical trials for this in several countries. Several medical agents produce some potency against visceral or cutaneous leishmaniasis, however a 2005 survey concluded that miltefosine is the only effective oral treatment for both forms of leishmaniasis. |
Cell Research | 2 × 105 PEL cells are treated with the therapeutic compounds at the indicated doses or with appropriate vehicle as a negative control. Cells are followed for 96 hours, and cell viability is determined by trypan blue exclusion performed in quadruplicate. (Only for Reference) |
Kinase Assay | Levels of enzymatically active caspase-3 are quantified using the ApoAlert Caspase Fluorescent assay kit. Briefly, 1×106 BC-1 PEL cells are treated with 50 μM Miltefosine, 50 μM Perifosine, or 20 nM NVP-BEZ235, as well as the respective vehicle controls. Cells are harvested and lysed 12 hours later. Equivalent micrograms of cell lysate for all samples are incubated with a fluorogenic caspase-3 substrate (DEVD-AFC). Cleavage of DEVD by caspase-3 releases AFC, the fluorescence of which is measured using a FLUOstar OPTIMA fluorometer, with excitation and emission filter wavelengths set to 400 and 505 nm, respectively[3]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | H2O : 10 mM DMSO : Insoluble |
Keywords | Miltefosine | PKB | inhibit | HIV | Inhibitor | Protein kinase B | Akt | Human immunodeficiency virus |
Inhibitors Related | Stavudine | 5-Fluorouracil | Emtricitabine | Kaempferol | Dolutegravir intermediate-1 | Dextran sulfate sodium salt (MW 4500-5500) | Lamivudine | Decanedioic acid | 2,3-Butanediol | Tenofovir |
Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | FDA-Approved Kinase Inhibitor Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$47.00/50mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
$0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-09-12 | |
$6.00/1KG |
VIP4Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2024-08-21 | |
$0.00/25kg |
Shaanxi Haibo Biotechnology Co., Ltd
|
2023-09-05 | ||
$50.00/1kg |
Anhui Ruihan Technology Co., Ltd
|
2023-08-23 | ||
$30.00/1KG |
Weijer International Trade (Hebei) Co., Ltd
|
2023-03-09 | ||
$0.00/1KG |
VIP4Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2023-01-10 | |
$1.00/1mg |
ANHUI SHENGZHIKAI BIOTECHNOLOGY CO.,LTD
|
2022-07-01 | ||
$20.00/1kg |
Hebei Linwo New Material Technology Co., LTD
|
2022-06-23 | ||
$10.00/1kg |
Jiangsu Bangdeya New Material Technology Co.,Ltd
|
2022-04-22 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY